

ESMO ADVANCED COURSE PROGRAMME

ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: THORACIC AND GENITOURINARY CANCERS

Zurich, Switzerland
25-26 November 2024

CO-CHAIRS	Solange Peters, Switzerland Thomas Powles, United Kingdom	SPEAKERS	Enriqueta Felip, Spain Yohann Loriot, France Michiel van der Heijden, The Netherlands
------------------	--	-----------------	---

LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

Monday, 25 November 2024

09:00-09:10	Welcome and introduction
10'	Welcome and Learning Objectives Introduction <i>Solange Peters, CH and Thomas Powles, UK</i>
09:10-09:30	Session 1 – Current landscape
10'	ADC Clinical Landscape in Lung Cancer <i>Solange Peters, CH</i>
10'	ADC Clinical Landscape in GU Cancers <i>Thomas Powles, UK</i>
09:30-10:35	Session 2 – ADC Development and pharmacodynamics
15'	Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance <i>TBC</i>
15'	Toxicity: Prediction, identification and treatment <i>TBC</i>

- 15' ADC development: What are the considerations in early phase trials
TBC
- 20' Discussion
- 10:35-11:05** *Coffee break*
- 11:05-11:40 **Session 3 – Target assessment and rationale for combinations**
- 20' Considerations from pathology: Biomarker selection, on-target, off-tumour expression, off-target toxicities
TBC
- 15' Discussion
- 11:40-12:35 **Session 4 – Next generation ADCs – Part I**
- 20' Developments in ADC constructs including: Bispecific ADCs,
TBC
- 20' Additional innovative strategies: Cytokine conjugates, peptide-based conjugates
TBC
- 15' Discussion
- 12:35-13:35** *Lunch*
- 13:35-14:05 **Session 4 – Next generation ADCs – Part II**
- 20' How to develop rational combinations and sequencing
Michiel van der Heijden, NL
- 10' Discussion
- 14:05-14:40 **Session 5 – Developments across diseases**
- 10' Future perspectives for lung cancer
Enriqueta Felip, ES
- 10' Future perspectives for GU cancers
Yohann Loriot, FR
- 15' Panel discussion: What can we learn from each other
Enriqueta Felip, ES, Yohann Loriot, FR, Solange Peters, CH, Thomas Powles, UK
- 19:30** *Networking dinner*

Tuesday, 26 November 2024

09:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

Workshop 1

ADC trials in GU (bladder cancer)

Yohann Lorient, FR

Michiel van der Heijden, NL

Workshop 2

ADC trials in thoracic cancers

TBC

Enriqueta Felip, ES

Workshop 3

ADC related toxicities

TBC

TBC

11:00-11:30

Coffee break

11:30-12:30

Workshops continuation

12:30-13:00

Feedback on the workshops from each group

13:00-13:15

Synthesis and wrap-up

Solange Peters, CH and Thomas Powles, UK

13:15-14:15

Lunch